Razelle Kurzrock

Oncology · 2008–2023

A researcher in the Science corpus: 13 papers; trusts 8 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Razelle Kurzrock trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Beth Levine
  2. J. Wolchok

Papers from Razelle Kurzrock's perspective

Ordered by how strongly the researchers Razelle Kurzrock trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
  3. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade (Proceedings of the National Academy of Sciences of the United States of America)
  4. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial (The Lancet)
  5. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
  6. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (New England Journal of Medicine)
  7. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma (Nature Medicine)
  8. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients (Nature)
  9. PD-1 blockade in tumors with mismatch repair deficiency. (Journal of Clinical Oncology)
  10. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (Clinical Cancer Research)

Their papers